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The 11th Sanibel Conference on Mass Spectrometry
sponsored by the American Society for Mass Spectrom-
etry had Mass Spectrometry in Clinical Diagnosis of Disease
as its topic. The conference was held at the Sundial
Conference Center in Sanibel Island, Florida, January
23–26, 1999. This year’s conference was organized by
Donald H. Chace (Neo Gen Screening, Inc., Pittsburgh,
PA) and Stephen Naylor (Mayo Clinic, Rochester, MN).
Again this year, the conference was fully subscribed
with 1401 participants. Other than a rather spectacular
thunderstorm on the opening night that resulted in a
large tree limb crashing through the windshield of
Sanibel Conference committee member Steve Lam-
mert’s parked rental car sometime after midnight, the
weather was some of the best seen in the 10-year history
of the Sanibel Conference—lots of sun and tempera-
tures in the high 70s and low 80s. There were 18 oral
presentations divided into 7 sessions, and 2 poster
sessions with a total of 21 posters (all the titles are listed
below). In addition to the invited posters, corporate
posters were presented by Micromass (Beverly, MA)
and PE Sciex (Foster City, CA) who, along with Park–
Davis Pharmaceutical Research (Ann Arbor, MI) (a
division of Warner Lambert Company), sponsored this
year’s conference.
As is always the case, with the amount of space
allocated for this type of review, it is impossible to do
justice to all the presentations. The following are some
of the highlights of the conference:
Dr. Chace and Dr. Naylor made opening remarks
that set the foundation for the conference. This founda-
tion was then firmly cemented by Larry D. Bowers
(Indiana Medical Center, Indianapolis, IN) in his pre-
sentation entitled Bridging the Gap Between Research and
Clinical Diagnosis. Dr. Chace stated that the contribu-
tions of mass spectrometry to clinical diagnostics have
been “better accuracy, enhanced selectivity, improved
precision, and increased sensitivity.” He went on to say
that by mixing mass spectrometry fundamentals with
laboratory medicine, new and novel applications re-
sulted in what has become known as clinical mass
spectrometry. Dr. Naylor pointed out that this year’s
Sanibel Conference was somewhat a deviation from the
past two years in that there was less of a focus on
instrumentation. He said that presenters had been
asked to speak less about their individual research and
to focus on mass spectrometry as a tool in clinical
diagnostics. To paraphrase Dr. Naylor’s opening com-
ments, “The purpose of the Conference is to educate
and illuminate the participants in the potential of and
the needs from mass spectrometry for clinical diagnos-
tics.”
Dr. Bowers covered a lot of the history of mass
spectrometry in the understanding of human health
and disease, but pointed out that mass spectrometry in
the routine evaluation and monitoring of patients is
very limited. This is due to the hypotheticodeductive
reasoning process of the clinician; and, to an even larger
extent (at least in the United States), the philosophy of
managed health care.
The hypotheticodeductive process is where the clini-
cian receives information from the patient. From this
information, an initial hypothesis is formed that results
from the specificity of the symptoms. Based on this
initial hypothesis, the clinician decides if additional
information (results of test—which could involve the
use of mass spectrometry) is necessary. With the new
information, the hypothesis can be revised. Based on
the additional information, action is taken to treat the
patient. More information may be required before treat-
ment begins. This renews the cycle of new information
to a revised hypothesis that results in another decision
for a different action, or the original action may involve
further testing to monitor the prescribed therapy. The
hypotheticodeductive process fits very well within the
combined dictionary definition of the words clinical and
diagnosis presented by Dr. Bowers: clinical—having to
do with medical study or practice based on actual
treatment and observation of patients as distinguished
from experimental or laboratory study; diagnosis—the
act or process of deciding the nature of a diseased
condition by examination.
Dr. Bowers pointed out that for mass spectral data to
be of benefit to the clinician, the results have to be
presented in an easy-to-understand form—not spectra
that require sophisticated interpretation. Samples taken
for analysis must not result in an overburdening pro-
cess for the patient. A good example of the latter is a test
that was devised to determine if a gastric ulcer was a
result of an H. pylori infection. Because H. pylori con-
verts urea to CO2, the patient had to drink a solution
that contained 13C-labeled urea. The patient then had to
breathe into a mass spectrometer every four hours. This
process was unacceptable because of the amount of
time the patient needed to expend on the test.
Research and method validation are required to
develop a clinical diagnostic mass spectrometric
method. Because of the cost-cutting that has taken place
in the clinical laboratory (largely as a result of an
increase in third-party payers and “for-profit” health
maintenance organizations—HMOs), the clinical labo-
ratory is no longer staffed with personnel that can
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validate the method or interpret the results. This means
that the researcher who develops the method is also
going to have to undertake the task of validation. Much
of the validation and research in regards to patient
testing that has been carried out in university medical
centers is disappearing because these third-party payers
are not willing to pay for services from medical stu-
dents. This has led to the merging of university medical
centers and “not-for-profit” health providers with
HMOs.
Dr. Bower’s presentation was not entirely negative.
He did state that there is a good future for the broader
prospects of mass spectrometry in clinical diagnostics.
However, this will require a number of factors: (1)
remove the perception that mass spectrometry is an
unreliable and difficult-to-use technology; (2) develop
turnkey mass spectrometry systems that incorporate
reagents and interpretation; (3) require that the mass
spectrometry scientist work with clinical colleges to
take characterized assays and achieve “reimbursable
status”; (4) focus on methods that can diagnose more
than one disease (e.g., newborn screening); (5) recog-
nize opportunities outside the individual clinical labo-
ratory (regional centers); (6) train scientists to be man-
agers of information and decision makers. These steps
must be taken not only by the scientist in the research
lab, but they must also drive the developments of the
instrument manufacturers for mass spectrometry to
become widely used tools for the clinical diagnosis of
disease.
Two main issues that have been continually para-
mount in recent symposia on mass spectrometry in
disease diagnosis and drug discovery have been sample
handling and data management. Jack Henion (Ad-
vanced BioAnalytical Services, Ithaca, NY) and others
pointed out that often the amount of data that could be
obtained was not limited by the mass spectrometry
analysis, but by the time required for sample prepara-
tion. As Dr. Henion (and others) has said many times,
“Time is money!” This is especially true with mass
spectral clinical analysis coming under the scrutiny of
managed health care. An important factor in the use of
mass spectrometry in clinical diagnosis is to reduce the
time and effort to perform the sample preparation. Dr.
Henion further stated that autosamples and modified
autopreparation systems combined with autosamplers
have helped a great deal, but care must be taken to
avoid and detect carryover, which is often a problem.
As pointed out by Dr. Chace in his presentation
entitled Newborn Screening for Genetic Disease using Elec-
trospray Tandem Mass Spectrometry, the widest use of
mass spectrometry has been in the area of newborn
screening. His company has used MS/MS to analyze
blood spots from more than 650,000 newborns for .20
inherited genetic disorders of metabolism. Each of three
electrospray MS/MS instruments is performing these
tests on 250,000 samples annually. This has only been
possible by the institution of the following: (1) systems
for the monitoring of mass spectral data quality, (2)
maintenance protocols for the instrumentation, and (3)
rapid-computer-based data processing for assisted au-
tomated interpretation and quantitation. However,
John F. O’Brien, M.D. (Department of Laboratory Med-
icine and Pathology, Mayo Clinic, Rochester, MN)
voiced a concern about the possible number of false
negatives and the humanitarian repercussions of a false
negative when so many samples have to be processed.
No conference is complete without the coining of at
least one new term. This year’s new term from Sanibel
came from Steve Naylor in his joint presentation with
John O’Brien. The new word is bioanalyticinfomationalist.
This is the person responsible for the interpretation of
the bioanalytical information generated by the mass
spectrometry technician into terms that provide the
information component of the physician’s hypotheti-
codeductive process. With these clinical neologisms and
the biochemical technospeak, the understanding of the
analytical chemist/mass spectrometrist sometimes be-
gins to fog over.
The organizers did a very good job in inviting
speakers who not only covered specifics of mass spec-
trometry in clinical diagnosis and the instrumental
needs for such analyses, but also covered the regulatory
and information management side of the equation.
Regulatory issues were addressed by Dr. Harry
Hannon (Centers for Disease Control (CDC), Atlanta,
GA) in his presentation CLIA, Quality Assurance and
Dried-Blood Spot. CLIA is the acronym for the Clinical
Laboratory Improvement Amendment of 1988. Interest-
ingly enough, even though CLIA grew out of the
mishandling of pap smears in the 1970s, these tests are
specifically exempt for CLIA regulation. All laborato-
ries that analyze human biological samples must be
CLIA certified. Dr. Hannon’s group at CDC is a profi-
ciency test materials provider for the analysis of blood
spots. Many of the mass spectrometry tests performed
by clinical laboratories do not have proficiency test
providers. The most notable among them is the tandem
mass spectrometry test for medium-chain acyl-coen-
zyme A dehydrogenase deficiency (MCAD). In cases
such as that of the MCAD analysis, the clinical labora-
tory has to provide results of self-administered profi-
ciency testing. This can greatly add to the cost of an
analysis.
One point revealed in Dr. Hannon’s presentation
was that the State of California has been storing blood
spots of all newborns for the last ten years. This was
noted with great interest by Adelbert Rosher (Univer-
sity of Munich, Munich, Germany), the closing speaker
for the conference, in the discussion period that fol-
lowed Dr. Hannon’s presentation. Dr. Rosher stated
that German law specifically prohibits the collection
and storage of blood spots of newborns by the govern-
ment, clearly stating that this material is the sole prop-
erty of the individual.
Two presentations addressed the issues of data: Some
Issues in Quantification by Al Yergey (National Institutes
of Health, Bethesda, MD) and Interpretation of Complex
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Laboratory Data using Neural Networks and Expert Systems
by Denis Lehotay (University of Toronto, Toronto,
Canada). With what at first appeared to be a rather
noncontroversial title, Dr. Yergey’s presentation sur-
prisingly elicited the most vigorous discussion of the
meeting. This pointed out the importance of issues of
quantitation in clinical analyses.
Keeping with a tradition that began last year, Joseph
E. Campana, the Chairperson of the Sanibel Committee,
announced the topic for the aught-n-aught (year 2000)
conference: Field Portable and Miniature Mass Spectrome-
ters (organized by Henk Meuzelaar of the University of
Utah, Salt Lake City, UT, and Marcus Wise of the Oak
Ridge National Laboratory, Oak Ridge, TN).
A list of the previous Sanibel Conference topics,
along with attendance, is found at the end of this article.
The following is a listing of the 1999 Sessions with
oral presentations:
SESSION 1: Clinical Chemistry and Mass Spectrom-
etry Today
Bridging the Gap Between Research and Clinical Diagno-
sis; Larry D. Bowers, Indiana Medical Center, Indianap-
olis, IN.
SESSION 2: Mass Spectrometry and the Detection of
Important Diagnostic Metabolites
Lipid Mediators of Inflammation: A Cascade of Eico-
sanoids Amenable to Tandem Mass Spectrometry; Robert C.
Murphy, National Jewish Medical & Research Center,
Denver, CO.
Determination of LTE4 in Human Urine by Liquid Chro-
matography Coupled with Ion Spray Tandem Mass Spec-
trometry; Jack Henion, Advanced BioAnalytical Ser-
vices, Inc., Ithaca, NY.
MALDI-Potential for Clinical Diagnosis; David Her-
cules, Vanderbilt University, Nashville, TN.
Screening of Homocysteine in Newborns; E. Solheim,
University of Bergen, Bergen, Norway.
Newborn Screening for Genetic Disease using Electros-
pray Tandem Mass Spectrometry; Donald H. Chace, Neo
Gen Screening, Pittsburgh, PA.
SESSION 3: From Metabolites to Proteins, New Ho-
rizons in Clinical Testing
Charge Reduction Electrospray Mass Spectrometry;
Mark Scalf, University of Wisconsin, Madison, WI.
The Use of Electrospray Tandem Mass Spectrometry in
the Study of Human Haemoglobin; Michael Morris, Micro-
mass, Manchester, United Kingdom.
Correlating Protein Expression with Disease: A Protein
Chemistry Perspective; Scott D. Patterson, Amgen Inc.,
Thousand Oaks, CA.
SESSION 4: Biopolymers—Analyses with a Twist
BioProteometics of Colon Cancer and Pro Interaction Map-
ping Complexed Biochemical Pathways; Richard J. Simp-
son, Ludwig Institute, Parkville, Australia.
Resolution and Quantitation of Transferrin Isoforms in
Clinical Conditions Affecting Protein Glycosylation; Ste-
phen Naylor, Mayo Clinic, Rochester, MN.
Accurate DNA Analysis by DNA MassArray™, An-
dreas Braun, Sequenom Institute, San Diego, CA.
Sugar and DNA Biomarkers Identified using Mass Spec-
trometry; Alvin Fox, University of South Carolina, Co-
lumbia, SC.
SESSION 5: Role of Carbohydrates and Disease
Carbohydrates in Disease Processes; Vernon Reinhold,
University of New Hampshire, Durham, NH.
The Role of Surface Carbohydrates in the Pathobiology of
Haemophilus and Neisseria: Structure, Function, Therapeu-
tics (and Diagnostics?); Bradford Gibson, University of
California, San Francisco, CA.
SESSION 6: Fundamentals: A Required Component
in Clinical Analyses
Some Issues in Quantification; Al Yergey, National
Institutes of Health, Columbia, MD.
Interpretation of Complex Laboratory Data using Neural
Networks and Expert Systems; Denis Lehotay, University
of Toronto, Ontario, Canada.
CLIA, Quality Assurance, and Dried-Blood Spot; Harry
Hannon, Centers for Disease Control, Atlanta, GA.
SESSION 7: Clinical Chemistry and Mass Spectrom-
etry in the Next Millennium
Mass Spectrometry in Clinical Diagnostics. Towards new
Horizons in Providing Healthcare Solutions; Adelbert Ros-
cher, University of Munich, Munich, Germany.
The following posters were presented:
The Evaluation of a New Compact Tandem Mass Spec-
trometer for Research into Inborn Errors of Metabolism
(IEM); Bori Shushan and Joe Anacleto, PE Sciex, On-
tario, Canada; Don H. Chace, Neo Gen Screening, Inc.,
Pittsburgh, PA.
Metabolite Identification of Nateglinide in Humans by
Liquid Chromatography Tandem Mass Spectrometry Meth-
ods; Elizabeth Graham, James B. Mangold, Lolita Rodri-
guez, Barbara Orwig, Margaret L. Weaver, Robert Tull-
man, and Volker Fischer, Novartis Pharmaceuticals,
Hanover, NJ.
Identification and Production of Novel Toxins Associated
with the Spanish Toxic Oil Syndrome; Ben Blout, Helen
Schurz-Rogers, Rossanne Philen, and Larry Needham,
National Center for Environmental Health, Centers for
Disease Control and Prevention, Atlanta, GA.
Facile Measurement of Trimethylamine and Trimethyl-
amine Oxide in Urine by Fast Atom Bombardment; O. A.
Mamer and L. Choiniere, McGill University, Montreal
Canada; E. Treacy, Montreal Children’s Hospital, Mon-
treal, Canada.
An Advanced Chemical Diagnostic Method Using Urine-
Filter Paper Set and GC/MS for Inborn Errors of Metabo-
lism; Isamu Matsumoto and Chunhua Zhang, Matsu-
moto Institute of Life Science, Kanazawa, Japan.
Breath Analysis for the Detection and Monitoring of
Several Disease States; Donald V. Kenny, Sydney M.
Gordon, Patrick J. Callahan, and Marielle M. Brinkman,
Battelle Memorial Institute, Columbus, OH.
Characterization of Phosphoinositides and Phosphocho-
lines from MCF-7 Human Breast Carcinoma Cells Using
Electrospray Ionization Tandem Mass Spectrometry; S. A.
Shaffer, E. Nudelman, and R. E. Finney, Cell Therapeu-
tics, Inc., Seattle, WA.
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Mass Spectrometric Detection of Increased Lipid Peroxi-
dation in Patients and Congestive Heart Failure; Denis C.
Lehotay, Susanna Mak, Peter P. Liu, and Gary E.
Newton, University of Toronto and Mount Sinai Hos-
pital, Toronto, Canada.
Determination of Potential Diagnostic Biomarkers for
Onset of Alzheimer’s Disease: Role of On-Line Chromatog-
raphy Mass Spectrometry; Nigel J. Clarke, Steven G.
Youkin, and Stephen Naylor, Mayo Clinic, Rochester,
MN.
Probing Antigen Structure and Antigen–Antibody Inter-
actions Using Synchrotron Radiation and Mass Spectrome-
try; Simin D. Maleknia, Janna G. Kiselar, Mark R.
Chance, and Kevin M. Downard, Albert Einstein Col-
lege of Medicine, New York.
Quantification Hbalc by Mass Spectrometry and Capillary
Electrophoresis; John R. Barr, Vincent L. Maggio, Adrian
R. Woolfitt, and Maria Ospina, Centers for Disease
Control and Prevention, Atlanta, GA.
New Isoforms of A and C Apolipoproteins were Discov-
ered in Human Serum HDL and VLDL using MALDI-TOF
and ESI-TOF MS; P. V. Bondarenko, Thermo BioAnaly-
sis Corp., Santa Fe, NM; L. K. Watkins, S. J. Cockrill,
and R. D. Macfarlane, Texas A & M University, College
Station, TX.
Application of HPLC-MS for Structural Studies on Tu-
mor-Marker Sialo-Glycoproteins; Krisztina Ludanyi and
Karoly Vekey, Hungarian Academy of Sciences, Budap-
est; Tibor Kremmer, Sandor Olah, and Edes Boldizsar,
National Oncological Institute, Budapest.
Transthyretin Mutant Detection Using Immunoprecipi-
tation and Bioreactive MALdI Probes; R. Theberge, M.
Skinner, L. Connors, and C. E. Costello, Boston Univer-
sity School of Medicine, Boston, MA.
MALDI-ToF Mass Spectrometry in the Diagnosis of
Pancreatic Cysts; Darryl E. Palmer-Toy, David Sarracino,
Kent Lewandrowski, and Peter Leopold, Massachusetts
General Hospital, Boston, MA, and ProteiGene Inc.,
Billerica, MA.
Strategies for High-Throughput Analysis of Polymorphic
Microsatellites by MALdI-TOF Mass Spectrometry; S. Hah-
ner, S. Mehl, M. Schuerenberg, and J. Mosner, Genom
Analytik GmbH, Bremen, Germany; K.-O. Krauter,
Bruker Daltonik GmbH, Bremen, Germany.
Markers of Peroxynitrite Exposure in DNA; N. Yu.
Tretyakova, J. C. Niles, J. S. Wishnok, and S. R. Tannen-
baum, MIT, Cambridge, MA.
ESI-FTICR Mass Spectrometry for the Characterization of
Variable Number Tandem Repeat Diseases and Single Nu-
cleotide Polymorphisms; Jason W. Flora, James C. Hannis,
Eric F. Gordon, Allison P. Null, and David C. Muddiman,
Virginia Commonwealth University, Richmond, VA.
Development of ESI-TOFMS for Detection of Uracil
Misincorporation in Human DNA; Mary E. Gimon-Kinsel,
Sensar Larson-Davis, Inc., Provo, UT; James Griener
and Barton A. Kamen, The University of Texas South-
western Medical Center at Dallas, Dallas, TX.
Accurate Genotyping using DNA MassArray; Martin
Schurenberg, Karl-Otto Krauter, Detlev Suckau, Armin
Holle, and Jens Hohndorf, Bruker Daltonik GmbH,
Bremen, Germany; Thomas Becker, Sequenom Instru-
ments GmbH, Hamburg, Germany; Dan Little, Seque-
nom Inc., San Diego, CA.
Previous topics of Sanibel Conferences:
1989
Topic Mechanisms of Ion Desorption
Organizers Mark Ross and Robert Cotter
Attendance 100
1990
Topic Ion Trapping
Organizers Gary Glish and Michelle Buchanan
Attendance 125
1991
Topic Ion Activation
Organizers Richard Caprioli and Robert Boyd
Attendance 100
1992
Topic Lasers in Mass Spectrometry
Organizers Tom Baer and Klaus Biemann
Attendance 127
1993
Topic Carbohydrates in Mass Spectrometry
Organizers Vern Rienhold
Attendance 78
1994
Topic Polymer Science
Organizers Robert Lattimer and Stan Israel
Attendance 130
1995
Topic Physics of Electrospray
Organizers Robert Voyksner and Paul Kebarle
Attendance 150
1996
Topic Metal Ions Chemistry
Organizers John Amster and Jennifer Broadbelt
Attendance 45
1997
Topic Quadrupole Ion Traps
Organizers Gary Glish and Ray March
Attendance 135
1998
Topic Time-of-Flight Mass Spectrometry
Organizers Brian Chait and Murray Johnson
Attendance 150
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